In this article, a method is presented to estimate a new local quality measure for 3D cryoEM maps that adopts the form of a `local resolution' type of information. The algorithm (DeepRes) is based on deep-learning 3D feature detection. DeepRes is fully automatic and parameter-free, and avoids the issues of most current methods, such as their insensitivity to enhancements owing to B-factor sharpening (unless the 3D mask is changed), among others, which is an issue that has been virtually neglected in the cryoEM field until now. In this way, DeepRes can be applied to any map, detecting subtle changes in local quality after applying enhancement processes such as isotropic filters or substantially more complex procedures, such as model-based local sharpening, non-model-based methods or denoising, that may be very difficult to follow using current methods. It performs as a human observer expects. The comparison with traditional local resolution indicators is also addressed.

A detailed study on chiral compound structures found in the Cambridge Structural Database (CSD) is presented. Solvates, salts and co-crystals have intentionally been excluded, in order to focus on the most basic structures of single enantiomers, scalemates and racemates. Similarity between the latter and structures of achiral monomolecular compounds has been established and utilized to arrive at important conclusions about crystallization of chiral compounds. For example, the fundamental phenomenon of conglomerate formation and, in particular, their frequency of occurrence is addressed. In addition, rarely occurring kryptoracemates and scalemic compounds (anomalous racemates) are discussed. Finally, an extended search of enantiomer solid solutions in the CSD is performed to show that there are up to 1800 instances most probably hiding among the deposited crystal structures, while only a couple of dozen have been previously known and studied.

A study on chiral monomolecular compound structures found in the Cambridge Structural Database is presented.

Subjects watched demonstrators for varying amounts of time. When given the pipe, each of the subjects in both groups opened the door on their first attempt using the method they had seen demonstrated.

The post Lemurs exhibit ability for social learning in zoo experiment appeared first on Smithsonian Insider.

The scale of the universe can be difficult to comprehend. Pretend you are going to make a scale model with a basketball representing the Earth […]

The post Can iPads help students learn science? appeared first on Smithsonian Insider.

Well known for its collection of children’s books, the Cooper Hewitt Library holds a rare 19th century illustrated German nursery rhyme children’s book titled Paradiesfibel, written and illustrated […]

The post Learning to sign: Rare book appeared first on Smithsonian Insider.

Several weeks before it went on display in mid-November at the Smithsonian’s National Museum of Natural History, minerals curator Jeff Post stood in the museum’s […]

The post Colossal diamond’s eerie glow earns it a fiery name appeared first on Smithsonian Insider.

Single-wavelength X-ray anomalous diffraction (SAD) is a frequently employed technique to solve the phase problem in X-ray crystallography. The precision and accuracy of recovered anomalous differences are crucial for determining the correct phases. Continuous rotation (CR) and inverse-beam geometry (IBG) anomalous data collection methods have been performed on tetragonal lysozyme and monoclinic survivin crystals and analysis carried out of how correlated the pairs of Friedel's reflections are after scaling. A multivariate Bayesian model for estimating anomalous differences was tested, which takes into account the correlation between pairs of intensity observations and incorporates the a priori knowledge about the positivity of intensity. The CR and IBG data collection methods resulted in positive correlation between I(+) and I(−) observations, indicating that the anomalous difference dominates between these observations, rather than different levels of radiation damage. An alternative pairing method based on near simultaneously observed Bijvoet's pairs displayed lower correlation and it was unsuccessful for recovering useful anomalous differences when using the multivariate Bayesian model. In contrast, multivariate Bayesian treatment of Friedel's pairs improved the initial phasing of the two tested crystal systems and the two data collection methods.

The post Learn about the National Zoo’s flamingo flock with keeper Sara Hallager appeared first on Smithsonian Insider.

School's nearly back in session, but the seven young lions at the Smithsonian's National Zoo have been working hard through the summer months!

The post Lion cub summer school: Instead of learning their ABCs, the National Zoo’s lion cubs are learning behaviors that will help animal care staff evaluate their health. appeared first on Smithsonian Insider.

The post Learn about the ash that comes from volcanoes with Dr. Liz Cottrell, a geologist from the National Museum of Natural History appeared first on Smithsonian Insider.

The post Meet Smithsonian archaeologist Stephen Loring and learn how he came work at the Smithsonian’s Arctic Studies Center appeared first on Smithsonian Insider.

The post Conrad Labandiera, Smithsonian palentologist, studies fossils to learn how insects got along before flowering plants arrived appeared first on Smithsonian Insider.

Learn how to use the Smithsonian Wild website to find amazing camera trap photos of mammals from around the world

The post Learn to use the Smithsonian Wild website of amazing animal photos! appeared first on Smithsonian Insider.

Learning from the forest. Setting up a long-term forest research plot in a tropical dry forest in the heart of Panama City. Click here for […]

The post Learning from the forest appeared first on Smithsonian Insider.

How do you train a wild animal to come back to you after you have set it free? If it is a fringe-lipped bat, Trachops […]

The post Rockin’ out: Bats learn to love heavy metal music appeared first on Smithsonian Insider.

Recently a team of scientists working at the Smithsonian’s Tropical Research Institute in Panama, decided to try and learn for the first time just which body parts the gliding ant C. atratus uses to steer as they glide.

The post Gliding ants steer with hind legs as they fly backwards, scientists learn appeared first on Smithsonian Insider.

Many public school students receive little or no exposure to the theory of evolution, the most important concept in understanding biology, says a new guidebook from the National Academy of Sciences (NAS).

American students progress toward proficiency in mathematics requires major changes in instruction, curricula, and assessment in the nations schools, says a new report from the National Research Council of the National Academies.

Each year, tens of millions of Americans, young and old, choose to learn about science in informal ways -- by visiting museums and aquariums, attending after-school programs, pursuing personal hobbies, and watching TV documentaries, for example.

Educational and business leaders want todays students both to master school subjects and to excel in areas such as problem solving, critical thinking, and communication

As researchers’ and teachers’ understanding of how best to learn and teach science evolves and curricula are redesigned, many teachers are left without the experience needed to enhance the science and engineering courses they teach, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Despite their potential, many English learners (ELs) -- who account for more than 9 percent of K-12 enrollment in the U.S. -- lag behind their English-speaking monolingual peers in educational achievement, in part because schools do not provide adequate instruction and social-emotional support to acquire English proficiency or access to academic subjects at the appropriate grade level, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Policymakers, employers, and educational institutions should take steps to strengthen the nation’s skilled technical workforce, says a new report from the National Academies of Sciences, Engineering, and Medicine.

A new report from the National Academies of Sciences, Engineering, and Medicine highlights the dynamic process of learning throughout the life span and identifies frontiers in which more research is needed to pursue an even deeper understanding of human learning.

A shift is needed in how science, technology, engineering, and mathematics (STEM) subjects are taught to students in grades K-12 who are learning English, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Scientific research that involves nonscientists contributing to research processes – also known as ‘citizen science’ – supports participants’ learning, engages the public in science, contributes to community scientific literacy, and can serve as a valuable tool to facilitate larger scale research, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Centering science instruction around investigation and design can improve learning in middle and high schools and help students make sense of phenomena in the world around them.

Between one-third and one-half of U.S. clinicians experience burnout and addressing the epidemic requires systemic changes by health care organizations, educational institutions, and all levels of government, says a new report from the National Academy of Medicine.

A new report from the National Academies of Sciences, Engineering, and Medicine recommends ways to make supply chains -- the systems that provide populations with critical goods and services, such as food and water, gasoline, and pharmaceuticals and medical supplies – more resilient in the face of hurricanes and other disasters, drawing upon lessons learned from the 2017 hurricanes Harvey, Irma, and Maria.

Source: Streetwise Reports   04/23/2020

Global healthcare packaging components manufacturer company West Pharmaceutical Services Inc. (WST:NYSE) today announced financial results for its first quarter ending March 31, 2020 and provided updated full-year 2020 financial guidance.

The company reported that net sales in Q1/20 increased to $491.5 million, a 10.8% increase from $443.5 million in Q1/19. During the same corresponding period, the firm stated that non-GAAP diluted earnings per share (EPS) increased by 36% to $0.99 and non-GAAP adjusted-diluted EPS increased by 36% to $1.01.

West Pharmaceutical Services advised that it is maintaining its FY/20 net sales guidance, which is expected to be in a range of $1.95-1.97 billion. The company stated that it is updating FY/20 adjusted-diluted EPS guidance to a new range of $3.52-3.62, compared to the prior estimated range of $3.45-3.55.

The company's President and CEO Eric M. Green commented, "During these unprecedented times, our priorities are focused on the well-being and safety of our team members as well as ensuring the supply of critical, high-quality components and solutions to our customers...I am extremely pleased that we delivered a strong performance in the first quarter given the challenging environment that the COVID-19 pandemic has had on our customers, our suppliers and our team members. In particular, we continued to deliver strong sales growth in high-value products, as demand trends from our worldwide customer base were similar to trends we saw last year. Our teams are partnering with a broad range of customers working to support efforts to develop solutions that address the global COVID-19 pandemic such as diagnostics, anti-viral therapeutics and vaccines."

The firm outlined sales in the most recent quarter by product line. The company reported that in Q1/20, net sales in its Proprietary Products segment grew by 9.7% to $373.5 million and that this segment "saw good demand for Westar^®, Daikyo^®, NovaPure^® and FluroTec^® components as well as for devices such as Daikyo Crystal Zenith^® syringes and cartridges and our self-injection platforms."

The firm noted that net sales from its Contract-Manufactured Products segment grew by 14.5% to $118.1 million led by sales of components for diagnostic devices and drug-injection delivery devices.

The company added that the Biologics market unit enjoyed double-digit organic sales growth, the Generics market unit achieved high-single digit organic sales growth and the Pharma market unit registered mid-single digit organic sales growth.

The firm additionally noted that during Q1/20 under its share repurchase program, it repurchased 761,500 shares for $115.5 million at an average share price of $151.65.

West Pharmaceutical Services is headquartered in Exton, Pa., roughly 35 miles west of Philadelphia, and is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems.

West Pharmaceutical has market capitalization of around $13.5 billion with approximately 73.84 million shares outstanding. WST shares opened 5.25% higher today at $179.05 (+$8.93, +5.25%) over yesterday's $170.12 closing price and reached a new 52-week high price this morning of $190.27. The stock has traded today between $177.13 and $190.27 per share and is currently trading at $187.04 (+$17.17, +10.11%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: WST:NYSE, )

Source: Streetwise Reports   05/01/2020

Seattle Genetics Inc. (SGEN:NASDAQ) yesterday announced financial results for the first quarter ended March 31, 2020.

The company also provided an update on commercial results achieved in the quarter for its lead medicines including ADCETRIS® (brentuximab vedotin) and PADCEV^™ (enfortumab vedotin-ejfv) and the U.S. Food and Drug Administration's (FDA) approval and launch of TUKYSA^™ (tucatinib).

The company's President and CEO Clay Siegall, Ph.D., commented, "We have had a remarkable start to 2020, delivering record product sales in the first quarter that are now coming from both ADCETRIS and PADCEV. Notably, strong PADCEV sales in the first full quarter of launch reflect the unmet need among patients with metastatic bladder cancer...With the recent approval of TUKYSA for patients with metastatic HER2-positive breast cancer, we have now launched our third product just four months after our second...We are also preparing for European commercial operations and have hired general managers in major European markets ahead of potential ex-U.S. approvals of TUKYSA. With two new products, growing revenues, and an advancing pipeline of novel cancer programs, we have exciting prospects for future growth."

The company highlighted that ADCETRIS net sales in the U.S. and Canada increased by 22% to $164.1 million in Q1/20, compared to $135 million in Q1/19. The firm indicated that PADCEV net sales in the U.S. reached $34.5 million in Q1/20, which was its first full quarter of commercialization. The company added that royalty revenues in Q1/20 were $20.4 million and collaboration and license agreement revenues in Q1/20 totaled $15.6 million.

The firm reported a net loss for Q1/20 of $168.4 million, or $0.98 per diluted share, compared to net loss of $13.3 million, or $0.08 per diluted share for Q1/19. The company explained that "the net loss in Q1/20 included a net investment loss of $59.1 million primarily associated with its common stock holdings in Immunomedics, which are marked-to-market, compared to a net investment gain of $38.1 million in Q1/19."

The company advised that its TUKYSA was approved by the FDA for patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2 regimens in the metastatic setting. The firm mentioned that it also expects to be able to report topline data in late Q2/20 or Q3/20 for the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment.

The company noted that it is regularly monitoring the effects of the COVID-19 situation and is maintaining its business outlook estimates for FY/20 that it provided previously on February 6, 2020. For FY/20 it expects ADCETRIS net product sales of $675–700 million, royalty revenues of $105–115 million and collaboration and license agreement revenues of $30–50 million. The firm advised that for FY/20 it expects that R&D expenses will range from $860–950 million with SG&A expenses of $475–525 million.

Seattle Genetics is headquartered in Bothell, Wash., and is a global biotechnology company focused on discovering and commercializing cancer medicines.

Seattle Genetics has a market capitalization of around $23.7 billion with approximately 172.5 million shares outstanding. SGEN shares opened 2.75% higher today at $141.00 (+$3.77, +2.75%) over yesterday's $137.23 closing price and reached a new 52-week high price this morning of $157.00. The stock has traded today between $140.05 and $157.00 per share and is currently trading at $148.51 (+$11.28, +8.22%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: SGEN:NASDAQ, )

Shares of Kraton Corp. traded 24% higher after the specialty polymers and high-value biobased products maker reported that net income in Q1/20 increased to $209.0 million, compared to $13.6 million in Q1/19.

The development of Green Infrastructure (GI) in a UK case study has been researched in a recent study. Some issues caused by an imbalance in stakeholder power and conflicting roles played by major stakeholders were identified with the project. Stakeholder participation is central to the concept of GI and the research reiterates the importance for those implementing GI to ensure that participation is effective and balanced.

Payments for Ecosystem Services (PES) schemes offer direct payments for communities and individuals in exchange for conserving areas of land reserved for conservation for their environmental qualities. The results of an Ecuadorian study highlight key aspects for designing successful PES schemes and demonstrate how investments associated with PES can also benefit poor communities.

Speed control, road traction, wipers when it rains, maintaining safe distances, collision avoidance, and lane change are some of the prominent features.

A pilot cloud-based learning platform that brings together multiple datasets, models and visualisation tools has been developed with the engagement of numerous stakeholders throughout the design process. This tool could lead to informed decisions about flood risk at the local level. These types of tools and frameworks are effective ways of facilitating better decision making.

The report titled "COVID-19: A wake up call for telecom service providers" is based on a survey conducted by QS I Guage, which rates colleges and universities in India with complete operational control held by London-based QS.

DDoS attacks during the first three months of this year have seen a significant spike in attacks on educational websites.

DDoS attacks during the first three months of this year have seen a significant spike in attacks on educational websites.

As many universities are moving quickly to distance learning, it is vital for educators to think carefully about how to adapt their approach to still deliver key learning outcomes for students in an online setting. Today’s guest blogger, Ramnarayan Krishnamurthy, is at the forefront supporting universities as they transition to distance learning. In his role as a Customer Success Engineer, he partners with educators to support them in achieving their goals for teaching and learning.... read more >>

CULPEPER — The Virginia Department of Transportation invites the public to attend one of three upcoming location and design public hearings about a...

CULPEPER — The Virginia Department of Transportation invites the public to attend a citizen information meeting to learn about the upcoming project...

Anthony Joshua's promoter Eddie Hearn says he does not want to stage the world heavyweight champion's next defence of his title behind closed doors.

The post Aussie learning platform trains Indonesian miners appeared first on The Lead SA.

Great British Bake Off semi-finalist, Stacey Hart, has taken on a new challenge - creating delicious treats without using refined sugar. Here the baker from Hertfordshire explains what prompted her to make changes and shares her recipes.

CELTIC Manor spa trainer Samantha Boyes has been moving quickly up the ranks in the year she has spent working at the five star resort.

COLONIAL HEIGHTS —The Virginia Department of Transportation (VDOT) will hold a public hearing for a proposed rehabilitation of the Route 46...

Proposed T-shaped intersection at Huguenot Trail, Huguenot Springs Rd. and Woolridge Rd. NORTH CHESTERFIELD —The Virginia Department of...